FIELD: chemistry.
SUBSTANCE: invention relates to novel imidazoquinoline derivatives or pharmaceutically acceptable salts thereof, tautomers thereof and pharmaceutically acceptable salts of tautomers, having general formula 
where R1 is -NR6R7, -(CH2)mCH=CH(CH2)nR9, -(CH2)mC=C(CH2)nR9 or -S(O)qR10; R2 is C1-6alkyl or C1-6alkyl which is substituted with one group selected from -OH and -OMe; each R4 and R5 is independently H, C6aryl-C1alkyl or a protective group; each of R6 and R7 is independently H, C1-6alkyl, C1-6alkyl which is substituted with one group selected from -OH and -OMe, C1-6alkoxy-C1-2alkyl or -(CH2)mCH=CH(CH2)nR9; each R9 is independently H, C1-6alkyl, or C6-10aryl; each R10 is independently C1-3alkyl or C6-10aryl-C1-6alkyl; each of m and n is independently equal to 0 or 1; and each q is independently equal to 0; provided that if R1 is -S-Me, R2 is isobutyl. The invention also relates to specific compounds, methods for synthesis of compounds of formulae 
and 
which are versions of formula I, a pharmaceutical composition based on formula I compounds and compositions based on formula I compounds and an additional immunogenic composition or antigen.
EFFECT: novel imidazoquinoline derivatives, which are suitable for modulating immune response in a subject, are obtained.
37 cl, 4 dwg, 2 tbl
